Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
Marion de Jong(Rotterdam University of Applied Sciences), Eric P. Krenning(Erasmus MC), C Smith(UCLouvain), Larry K. Kvols(Moffitt Cancer Center), François Jamar(Novartis (United States)), Willem H. Bakker(Erasmus MC), Wout A. P. Breeman(Uppsala University Hospital), Dik J. Kwekkeboom(Erasmus MC), Stanislas Pauwels, Roelf Valkema(Active Medicine (United Kingdom))
Cited by 347
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814